BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2230926
,
SLC12A1
,
cell-cell adhesion
,
Ischemia
,
Retina
,
Laryngoscope
,
Lovastatin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Tigit
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Spleen
Lymph nodes
Tonsil
Ileum mucosa
Thymus gland
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Meningitis
Exercise
Viral infections of the central nervous system
Disease due to Flaviviridae
Listeriosis
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
scytonemin
gp50 protein, Schistosoma
p40 egg antigen, Schistosoma
IL21 protein, human
N,N-dimethyl-4-anisidine
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
CHCHD2
RIPK1
EOMES
SSBP1
BACH2
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
TIGIT may Serve as a Potential Target for the Immunotherapy of Renal Cell Carcinoma.
Ectopic Expression of TIGIT in Lung Adenocarcinoma and Its Clinical Significance.
ImmunoPET imaging of TIGIT in the glioma microenvironment.
Enhancing immunity against Candida albicans infections through TIGIT knockout.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
TIGIT in Patients With Chronic Myeloid Leukemia
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ